This paper presents the first passive implantable microelectromechanical systems (MEMS) device for targeted intraocular delivery of therapeutic compounds. In particular, this device addresses the treatment of chronic, difficult to reach diseases that affect the retina including retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, and glaucoma. The device is composed of three structural polymethyldisiloxane (PDMS) layers that are irreversibly bonded without the use of any adhesives. These layers form an integrated drug delivery device consisting of a refillable reservoir, tube, check valve, and suture tabs. This device requires a single implantation surgery and is capable of repeated delivery of multiple drugs. Characterization of the refillable reservoir and check valve performance is presented. Preliminary surgical implantation results of a mechanical test structure are also presented.
INTRODUCTION
The ability to precisely administer pharmaceutical solutions to a specified target within the body, especially the eye, is an ongoing challenge in many areas of drug delivery. Pharmacologic management of ocular disease is particularly difficult as many factors limit drug efficacy. Traditional routes of ocular administration include systemic (oral drugs), topical (eye drops), intraocular and periocular (injections and sustained-release devices); however each of these approaches are less than optimal for chronic treatment of posterior segment eye diseases. These diseases, including retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, and glaucoma, are the leading causes for irreversible blindness in the world [1] .
The surface of the eye is a significant physical barrier to medications that target intraocular treatment sites. Topical eye drops must be able to permeate through the modified mucosal membrane that covers the cornea. Less that 500 of the topically delivered pharmaceuticals will reach the intraocular space [2] . As a result, topical delivery is ineffective and often unable to achieve the required therapeutic levels at the treatment site. Oral medications face similar challenges and must overcome the blood-retinal barrier. In addition, large systemic doses applied to reach therapeutic levels may result in unwanted side effects [1, 2] [5] [6] [7] . Dimensions for this ocular drug delivery device are selected such that the overall device is minimally invasive and comfortable for the patient. The device utilizes a passive delivery mechanism to eliminate the need for control electronics and thus reducing the cost of the system. In order for the device to be a viable treatment method for chronic diseases, it must be refillable to allow repeated dosing for many years. Once implanted, the device must precisely and repeatedly deliver accurate doses and hold enough medication for multiple doses prior to refilling (-every 2 months). The device should be flexible and conform to the natural curvature of the eye. An ocular drug delivery device and its placement relative to the eye (subconjunctival) are illustrated in Figure 1 . An illustration of the first device prototype is shown in Figure 2 . The reservoir is secured to the top of the eye, while the shunt is inserted into either the anterior or posterior chamber (Figure 3a) . A specific dose of medication is dispensed from the device when the reservoir is manually depressed by the patient's finger (Figure 3b ). The reservoir can be refilled with the same or different medication without additional surgery (Figure 3c ). ,ery device
The first prototype ocular drug delivery device integrates a refillable reservoir, transscleral cannula for drug delivery, and a check valve that is located at the end of the cannula. PDMS is selected for its flexibility and ability to reseal itself after repeated punctures via a syringe needle. This material selection also enables a refillable drug reservoir. The drug delivery tube diameter is set to less than 1 mm. For incisions of this size, the eye is able to maintain its integrity without the aid of sutures. Support posts are contained within the tube and the reservoir to prevent the top surfaces of the device from collapsing when the drug is depleted. A normally-closed check valve prevents backflow of fluids from the eye into the device. The valve opens above a certain cracking pressure allowing drug to be dosed from the The top layer was fabricated using a conventionally machined mold, whereas the middle and top layers are molded from silicon masters that were etched using DRIE. The silicon masters were then coated in parylene which serves as a release layer between the PDMS and silicon. Individual layers were then bonded together assisted by either oxygen plasma [9] or wet chemical surface treatment. Both methods alter the surface chemistry of PDMS from hydrophobic to hydrophilic; this change facilitates irreversible bonding of PDMS-to-PDMS without adhesives. Figure 5 shows a completely assembled drug delivery device. The operating characteristics of the check valve were determined by clamping the device in a custom testing apparatus and attaching the fixture to a water chamber pressurized by a nitrogen cylinder (Figure 8 ). In such a manner, pressurized water is forced through the delivery tube Applied Prsur IkPa Figure 9 . DI water flow rate vs. applied pressure for the integrated check valve (Mean±SE, n=4)
Surgical Implantation
The prototype device was utilized as a surgical test model for mechanical characterization from both surgical handling and operation perspectives. The device was implanted into an enucleated porcine eye. First, the reservoir portion was secured to the eye wall using the suture tabs and then the tube was directed into the anterior chamber through a small incision at the limbus (Figure 10 ). Based on preliminary surgical results, the device geometry requires adjustment to facilitate the implantation surgery.
Various device geometries are being considered and will be evaluated in 76 msm.. The concept for the second generation device is shown in Figure 11 and will conform to the eye contours and integrate flow regulating components that will deliver specific and repeatable dose volumes. It will also incorporate geometrical changes suggested by ophthalmic surgeons to facilitate implantation. The edges of device will be rounded in order to distribute stress and minimize dead volume. The refill port will be relocated to maximize accessibility after the device is implanted. Other materials for the refill port and device body are being investigated to further extend lifetime and mechanical robustness under surgical handling. A surgical procedure utilizing phenylephrine, a quick-acting dilating agent, to validate device functionality in vivo will be developed. Future versions will also explore electronically controlled pumping to achieve drug delivery. 
